Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05681780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

StatusRecruiting
PhasePhase 1
Started2023-03-10
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jun 2026 → Jun 2027
See other at-risk trials from H. Lee Moffitt Cancer Center and Research Institute

Amendment history

2026-09-17
Primary completion pushed: 2026-06 → 2027-06
2026-03-26
Active, Not Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v12
Trial statusActive, Not Recruiting→Recruiting
Primary completion date2025-12→2026-06
Enrollment target13→20
Study sitesdetails revised at 1 of 1 site
2025-12-02
Study Status v11
Re-verified, no change to tracked fields
2025-08-28
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v10
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 20→confirmed 13
Study sitesdetails revised at 1 of 1 site
2025-05-05
Study Status, Study Design v9
PhasePhase 1/2→Phase 1
Show 8 earlier versions
2025-02-04
Study Status v8
Primary completion date2025-01→2025-12
Completion date2027-01→2027-12
2024-12-10
Study Status v7
Primary completion date2026-02→2025-01
Completion date2027-02→2027-01
Start date2023-01-23→2023-03-10
2024-08-21
Study Status v6
Primary completion date2025-07→2026-02
Completion date2025-07→2027-02
2024-03-21
Study Status v5
Start date2022-12-23→2023-01-23
2023-10-17
Study Status, Contacts/Locations v4
Study sitescontacts updated at 1 of 1 site
2023-10-03
Study Status, Contacts/Locations v3
Study sitescontacts updated at 1 of 1 site
2023-09-27
Study Status, Contacts/Locations v2
Study sitescontacts updated at 1 of 1 site
2023-05-03
Study Status, Contacts/Locations v1
Study sitescontacts updated at 1 of 1 site
2022-12-28
Original filing
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.
Trial Details
NCT Number NCT05681780
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Conditions Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Enrollment 20 participants
Start Date 2023-03-10
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-16